British Medical Journal
22 October 2011 Volume 343, Issue 7828
http://www.bmj.com/content/current

Letter
Comparing HPV vaccines
HPV vaccine prices in Italy
Livio Garattini, Katelijne van de Vooren, Gianluigi Casadei

Extract
In contrast to what was reported in the editorial, both the bivalent (Cervarix) and the quadrivalent (Gardasil) vaccines are used in Italy for the campaign against cervical cancer. Most of the 20 Italian regions, which fund and implement vaccination programmes on their territory, ran single tenders to exploit potential competition between the two …

Letter
HPV vaccines
UK needs vaccine to protect against HPV types causing recurrent respiratory papillomatosis
Michael P Rothera, David M Albert, Owain R Hughes,

Extract
We are pleased that the Department of Health is reviewing which human papillomavirus (HPV) vaccine to use in the national immunisation programme. 1 As Jit and colleagues state, deciding between the bivalent and the quadrivalent vaccine is not straightforward. We would like to contribute to the decision making process by highlighting our experience of treating …

Letter
Comparing HPV vaccines
Changing face of HPV related cancer in the UK

Andrew G Schache, Richard Simcock, Duncan C Gilbert, Richard J Shaw

Extract
As the UK nears a decision on continuation of the national human papillomavirus (HPV) vaccination programme, Jit and colleagues’ economic evaluation of the available vaccines makes compelling reading. 1

When developing arguments for cost effectiveness of the bivalent and quadrivalent vaccines, the analysis bears heavily on available data for cervical cancer, …